Patents by Inventor Zhaozhong DING

Zhaozhong DING has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Crystal form A of 2-butoxy-7-(4-(pyrrolidin-1-ylmethyl)benzyl)-5H-pyrrolo[3,2-d]pyrimidin-4-amine for inhibiting toll-like receptor activity
    Patent number: 10947245
    Abstract: The present invention relates to crystalline form A of a TLR7 agonist 2-butoxy-7-(4-(pyrrolidin-1-ylmethyl)-benzyl)-5H-pyrrolo[3,2-d]pyrimidin-4-amine (formula I), a method for preparing the crystalline form A, and the use thereof.
    Type: Grant
    Filed: September 25, 2019
    Date of Patent: March 16, 2021
    Assignee: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Zhaozhong Ding, Fei Sun, Yinghu Hu, Yilong Zhou, Zheng Wang, Rui Zhao, Ling Yang
  • TLR7 AGONIST MALEATE SALT, CRYSTALLINE FORMS C, D AND E THEREOF, PREPARATION METHODS AND USES OF MALEATE SALT AND CRYSTALLINE FORMS
    Publication number: 20200368241
    Abstract: The present invention relates to a maleate salt of a compound represented by formula I, a method for preparing the salt, a pharmaceutical composition containing the salt, and the use of the salt. The present invention also relates to crystalline forms C, D and E of the maleate salt of the compound represented by formula I, methods for preparing the crystalline forms, crystalline compositions and pharmaceutical compositions containing the crystalline forms, and uses thereof.
    Type: Application
    Filed: August 12, 2020
    Publication date: November 26, 2020
    Inventors: Zhaozhong DING, Fei SUN, Yinghu HU, Yilong ZHOU, Zheng WANG, Ling YANG
  • TLR7 agonist maleate salt, crystalline forms C, D and E thereof, preparation methods and uses of maleate salt and crystalline forms
    Patent number: 10780091
    Abstract: The present invention relates to a maleate salt of a compound represented by formula I, a method for preparing the salt, a pharmaceutical composition containing the salt, and the use of the salt. The present invention also relates to crystalline forms C, D and E of the maleate salt of the compound represented by formula I, methods for preparing the crystalline forms, crystalline compositions and pharmaceutical compositions containing the crystalline forms, and uses thereof.
    Type: Grant
    Filed: February 4, 2017
    Date of Patent: September 22, 2020
    Assignee: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Zhaozhong Ding, Fei Sun, Yinghu Hu, Yilong Zhou, Zheng Wang, Ling Yang
  • METHOD FOR PREPARING PYRROLO[3,2,-D]PYRIMIDINE COMPOUND, AND INTERMEDIATES THEREOF
    Publication number: 20200239484
    Abstract: The present invention relates to a method for preparing a pyrrolo[3,2-d]pyrimidine compound (the compound represented by formula I), and corresponding intermediates.
    Type: Application
    Filed: April 13, 2020
    Publication date: July 30, 2020
    Inventors: Zhaozhong DING, Fei SUN, Yinghu HU, Yilong ZHOU, Rui ZHAO, Ling YANG
  • TLR7 agonist trifluoroacetate salt and crystalline form B thereof, preparation methods and uses
    Patent number: 10683296
    Abstract: The present invention relates to a trifluoroacetate salt of a TLR7 agonist 2-butoxy-7-(4-(pyrrolidin-1-ylmethyl)benzyl)-5H-pyrrolo[3,2-d]pyrimidin-4-amine (formula I), crystalline form B of the trifluoroacetate salt, methods for preparing the trifluoroacetate salt and crystalline form B, and uses of the trifluoroacetate salt and crystalline form B.
    Type: Grant
    Filed: February 4, 2017
    Date of Patent: June 16, 2020
    Assignee: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Zhaozhong Ding, Fei Sun, Yinghu Hu, Yilong Zhou, Zheng Wang, Rui Zhao, Ling Yang
  • 7-(thiazol-5-yl) pyrrolopyrimidine compound as TLR7 agonist
    Patent number: 10676478
    Abstract: The present invention relates to a 7-(thiazol-5-yl)pyrrolopyrimidine compound as a TLR7 agonist, and particularly relates to a compound shown in formula (I), pharmaceutically acceptable salt and preparation method thereof, a pharmaceutical composition containing such a compound, and usage thereof in preparing an antiviral drug.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: June 9, 2020
    Assignee: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Zhaozhong Ding, Fei Sun, Lifang Wu, Hao Wu, Shuhui Chen, Ling Yang
  • Method for preparing pyrrolo[3,2-D]pyrimidine compound, and intermediates thereof
    Patent number: 10654856
    Abstract: The present invention relates to a method for preparing a pyrrolo[3,2-d]pyrimidine compound (the compound represented by formula I), and corresponding intermediates.
    Type: Grant
    Filed: February 4, 2017
    Date of Patent: May 19, 2020
    Assignee: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Zhaozhong Ding, Fei Sun, Yinghu Hu, Yilong Zhou, Rui Zhao, Ling Yang
  • Pyrrolopyrimidine compounds used as TLR7 agonist
    Patent number: 10555949
    Abstract: The present invention relates to a pyrrolopyrimidine compound as TLR7 agonist, and particularly relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, a preparation process thereof, a pharmaceutical composition containing such compounds and use thereof for manufacturing a medicament against viral infection.
    Type: Grant
    Filed: April 17, 2018
    Date of Patent: February 11, 2020
    Assignee: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Zhaozhong Ding, Hao Wu, Fei Sun, Lifang Wu, Ling Yang
  • TLR7 AGONIST CRYSTALLINE FORM A, PREPARATION METHOD AND USE THEREOF
    Publication number: 20200039988
    Abstract: The present invention relates to crystalline form A of a TLR7 agonist 2-butoxy-7-(4-(pyrrolidin-1-ylmethyl)-benzyl)-5H-pyrrolo[3,2-d]pyrimidin-4-amine (formula I), a method for preparing the crystalline form A, and the use thereof.
    Type: Application
    Filed: September 25, 2019
    Publication date: February 6, 2020
    Inventors: Zhaozhong DING, Fei SUN, Yinghu HU, Yilong ZHOU, Zheng WANG, Rui ZHAO, Ling YANG
  • Crystal form A of 2-butoxy-7-(4-(pyrrolidin-1-ylmethyl)benzyl)-5H-pyrrolo[3,2-D] pyrimidin-4-amine, preparation process and use thereof
    Patent number: 10442811
    Abstract: The present invention relates to crystalline form A of a TLR7 agonist 2-butoxy-7-(4-(pyrrolidin-1-ylmethyl)-benzyl)-5H-pyrrolo[3,2-d]pyrimidin-4-amine (formula I), a method for preparing the crystalline form A, and the use thereof.
    Type: Grant
    Filed: February 4, 2017
    Date of Patent: October 15, 2019
    Assignee: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Zhaozhong Ding, Fei Sun, Yinghu Hu, Yilong Zhou, Zheng Wang, Rui Zhao, Ling Yang
  • TLR7 AGONIST MALEATE SALT, CRYSTALLINE FORMS C, D AND E THEREOF, PREPARATION METHODS AND USES OF MALEATE SALT AND CRYSTALLINE FORMS
    Publication number: 20190070179
    Abstract: The present invention relates to a maleate salt of a compound represented by formula I, a method for preparing the salt, a pharmaceutical composition containing the salt, and the use of the salt. The present invention also relates to crystalline forms C, D and E of the maleate salt of the compound represented by formula I, methods for preparing the crystalline forms, crystalline compositions and pharmaceutical compositions containing the crystalline forms, and uses thereof.
    Type: Application
    Filed: February 4, 2017
    Publication date: March 7, 2019
    Inventors: Zhaozhong DING, Fei SUN, Yinghu HU, Yilong ZHOU, Zheng WANG, Ling YANG
  • METHOD FOR PREPARING PYRROLO[3,2-D]PYRIMIDINE COMPOUND, AND INTERMEDIATES THEREOF
    Publication number: 20190040072
    Abstract: The present invention relates to a method for preparing a pyrrolo[3,2-d]pyrimidine compound (the compound represented by formula I), and corresponding intermediates.
    Type: Application
    Filed: February 4, 2017
    Publication date: February 7, 2019
    Inventors: Zhaozhong DING, Fei SUN, Yinghu HU, Yilong ZHOU, Rui ZHAO, Ling YANG
  • TLR7 AGONIST CRYSTALLINE FORM A, PREPARATION METHOD AND USE THEREOF
    Publication number: 20190040071
    Abstract: The present invention relates to crystalline form A of a TLR7 agonist 2-butoxy-7-(4-(pyrrolidin-1-ylmethyl)-benzyl)-5H-pyrrolo[3,2-d]pyrimidin-4-amine (formula I), a method for preparing the crystalline form A, and the use thereof.
    Type: Application
    Filed: February 4, 2017
    Publication date: February 7, 2019
    Inventors: Zhaozhong DING, Fei SUN, Yinghu HU, Yilong ZHOU, Zheng WANG, Rui ZHAO, Ling YANG
  • TLR7 AGONIST TRIFLUOROACETATE SALT AND CRYSTALLINE FORM B THEREOF, PREPARATION METHODS AND USES
    Publication number: 20190031666
    Abstract: The present invention relates to a trifluoroacetate salt of a TLR7 agonist 2-butoxy-7-(4-(pyrrolidin-1-ylmethyl)benzyl)-5H-pyrrolo[3,2-d]pyrimidin-4-amine (formula I), crystalline form B of the trifluoroacetate salt, methods for preparing the trifluoroacetate salt and crystalline form B, and uses of the trifluoroacetate salt and crystalline form B.
    Type: Application
    Filed: February 4, 2017
    Publication date: January 31, 2019
    Inventors: Zhaozhong DING, Fei SUN, Yinghu HU, Yilong ZHOU, Zheng WANG, Rui ZHAO, Ling YANG
  • 7-(THIAZOL-5-YL) PYRROLOPYRIMIDINE COMPOUND AS TLR7 AGONIST
    Publication number: 20180370976
    Abstract: The present invention relates to a 7-(thiazol-5-yl)pyrrolopyrimidine compound as a TLR7 agonist, and particularly relates to a compound shown in formula (I), pharmaceutically acceptable salt and preparation method thereof, a pharmaceutical composition containing such a compound, and usage thereof in preparing an antiviral drug.
    Type: Application
    Filed: November 4, 2016
    Publication date: December 27, 2018
    Inventors: Zhaozhong DING, Fei SUN, Lifang WU, Hao WU, Shuhui CHEN, Ling YANG
  • PYRROLOPYRIMIDINE COMPOUNDS USED AS TLR7 AGONIST
    Publication number: 20180303832
    Abstract: The present invention relates to a pyrrolopyrimidine compound as TLR7 agonist, and particularly relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, a preparation process thereof, a pharmaceutical composition containing such compounds and use thereof for manufacturing a medicament against viral infection.
    Type: Application
    Filed: April 17, 2018
    Publication date: October 25, 2018
    Inventors: Zhaozhong DING, Hao WU, Fei SUN, Lifang WU, Ling YANG
  • Preparation method for benzoxazoleoxazine ketone compound and intermediate and crystal form thereof
    Patent number: 10106557
    Abstract: A preparation method for a high-purity benzoxazoleoxazine ketone compound, a crystal form thereof, and an intermediate compound for preparing a compound of formula (I), and a preparation method therefor.
    Type: Grant
    Filed: September 23, 2015
    Date of Patent: October 23, 2018
    Assignee: NORTH CHINA PHARMACEUTICAL NEW DRUG R&D CO., LTD.
    Inventors: Shuhui Chen, Zhaozhong Ding, Gangli Gong, Xiaobing Yan, Wei Huang, Feng Guo, Baoling Duan, Renlong Gao, Pingfan Zhou, Xinhua Lu, Guimin Dong
  • Spirocyclic aryl phosphorus oxide and aryl phosphorus sulfide
    Patent number: 10053477
    Abstract: Disclosed is a spirocyclic aryl phosphorus oxide or sulfide as an ALK inhibitor, particularly, a compound represented by formula (I) as an ALK inhibitor or pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: August 21, 2018
    Assignee: QILU PHARMACEUTICAL CO., LTD.
    Inventors: Zhaozhong Ding, Minghui Zhang, Shuhui Chen, Xile Liu, Yidong Zhu, Chuanwen Fan, Baoping Zhao, Long Zhang, Yingying Yang, Qingmei Zheng, Shansong Zheng, Haiwen Wan, Jinqing Hu
  • Pyrrolopyrimidine compounds used as TLR7 agonist
    Patent number: 9962388
    Abstract: The present invention relates to a pyrrolopyrimidine compound as TLR7 agonist, and particularly relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, a preparation process thereof, a pharmaceutical composition containing such compounds and use thereof for manufacturing a medicament against viral infection.
    Type: Grant
    Filed: August 14, 2015
    Date of Patent: May 8, 2018
    Assignee: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Zhaozhong Ding, Hao Wu, Fei Sun, Lifang Wu, Ling Yang
  • Hydrazine compound as blood coagulation factor Xa inhibitor
    Patent number: 9938272
    Abstract: Provided is a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X is selected from a 3-9 membered carbon ring or a ring which is formed by 3-9 membered carbocyclic ring fused with benzo ring, and a 4-10 membered heterocyclic ring or a ring which is formed by 4-10 membered heterocyclic ring fused with benzo ring; Y and Z are independently selected from 4-9 membered saturated heterocyclic rings respectively; R1-3 are independently selected from H, F, Cl, Br, I, CN, OH, SH, NH2, CHO, COOH respectively, or selected from the group, optionally substituted by R01, consisting of C1-10 alkyl, C1-10 heteroalkyl, C3-10 cyclohydrocarbyl, C3-10 heterocyclohydrocarbyl, C1-10 alkyl substituted by C3-10 cyclohydrocarbyl or C3-10 heterocyclohydrocarbyl, and C1-10 heteroalkyl substituted by C3-10 cyclohydrocarbyl or C3-10 heterocyclohydrocarbyl.
    Type: Grant
    Filed: May 18, 2015
    Date of Patent: April 10, 2018
    Assignee: North China Pharmaceutical Company., Ltd.
    Inventors: Zhaozhong Ding, Guanghua Lai, Shuhui Chen, Xiaobing Yan